Anonymous
Guest
Anonymous
Guest
Spot on. Humira has already LOST some significant commercial Payor coverages lately. That's what matters. Period.
Ditto for Androgel. Two drugs with the weight of the entire company on their shoulders for the next year plus. Going to get leaned. Increased "share of voice" is finally recognized as a true negative to gaining acceptance. Its called "being a pest".
Faking calls to avoid this dilemma in the field, only underscores this. "Pesting" is not a viable sales technique in this healthcare environ. Sorry.
I heard the same thing from Juan yesterday.